Published on 31 May 2024 on Zacks via Yahoo Finance
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Gilead Sciences, Inc. GILD announced the failure of its late-stage confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer (mUC).
Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2-directed antibody-drug conjugate (ADC). It is approved in several countries for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies.